NCT06376253View on ClinicalTrials.gov

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 8, 2024

Primary Completion Date

July 10, 2025

Study Completion Date

July 10, 2025

Conditions
Ovarian CancerLung Cancer
Interventions
DRUG

[68Ga]Ga-EVS459

Radioligand imaging agent

DRUG

[177Lu]Lu-EVS459

Radioligand therapy

Trial Locations (1)

6423906

Novartis Investigative Site, Tel Aviv

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY